Deciduous Therapeutics
Deciduous is developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.
Deciduous is developing a novel class of immune-modulatory therapies designed to promote a healthy lifespan.
Deciduous Therapeutics is a biopharmaceutical company focused on developing immune-modulatory therapies to improve overall health-span. The company's mission is to target senescent cells, known for their contribution to age-related diseases, by activating endogenous immune surveillance mechanisms. By selectively removing these cells, Deciduous Therapeutics aims to ameliorate disease pathologies and promote a healthy lifespan. Founded in 2018 and headquartered in the United States, the company recently secured a $10.00M seed round investment from notable backers including Bold Capital Partners, Humboldt Fund, Owl Capital, and Healthspan Capital on 31 December 2022. With a focus on biopharma, biotechnology, and healthcare, Deciduous Therapeutics presents a promising opportunity for investors in the thriving life sciences sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $10.00M | 4 |
|
31 Dec 2022 |
| Seed Round | Unknown | 1 |
|
16 Jun 2022 |
| Seed Round | $6.50M | 4 |
|
28 Jun 2019 |
No recent news or press coverage available for Deciduous Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
